Table 4.
Drugs prescription comparison with previous registries from Spain
| ESC Heart Failure Long‐term Registry17 (LVEF ≤ 40%) (N = 1526) | Linx registry (N = 1056) | P value | |
|---|---|---|---|
| ACE‐I (%) | 64.6 | 48.1 | <0.001 |
| ARB (%) | 29.1 | 16.9 | <0.001 |
| ARNI (%) | — | 23.9 | — |
| ACE‐I + ARB + ARNI (%) | 92.6 | 86.9 | <0.001 |
| Beta‐blockers (%) | 93.3 | 91.8 | 0.15 |
| MRA (%) | 74.5 | 72.7 | 0.31 |
| Diuretics (%) | 83.3 | 83.5 | 0.89 |
| Digoxin (%) | 22 | 14.1 | <0.001 |
| Ivabradine (%) | 19.7 | 21.4 | 0.29 |
| Nitrates (%) | 16.8 | 19.7 | 0.06 |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; ESC, European Society of Cardiology; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.